---
document_datetime: 2025-09-09 10:16:03
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8984063
conversion_datetime: 2025-12-30 01:37:03.733106
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tenofovir disoproxil Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | A. ADMINISTRATIVE CHANGES - A.7 | 05/09/2025                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291054                     | Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.e.6 Change in any part of the (primary) packaging material not in contact with the finished product formulation (such as colour of flip-off caps, colour code rings on ampoules, change of needle shield (different plastic used)) - B.II.e.6.a Change that affects the product information - Accepted   |            |     | PL   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000268655 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e) Container closure system - B.II.e.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                            | 10/07/2025 | N/A |      |
| Variation type IA / EMA/VR/0000279866 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF                                                                                                                                                                                                                                                                                                                                                                                                    | 20/06/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

| holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted  A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted  A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                                         | a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type II / EMA/VR/0000224509                   | B.I ACTIVE SUBSTANCE - B.I.z Substantial updates to Mod. 3.2.S or the ASMF - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/02/2025 | N/A        |                        |
| Marketing Authorisation Transfer - H / EMA/T/0000224787 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Mylan Pharmaceuticals Limited to Viatris Limited                                                                                                                                                                                                                                                                                                                                                                                                            | 12/08/2024 | 04/10/2024 | SmPC, Labelling and PL |
| Variation type IA / EMA/VR/0000222292                   | A.2 Change in the (invented) name of the medicinal product - A.2.a) for Centrally Authorised products - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/07/2024 | 27/09/2024 | SmPC, Labelling and PL |
| Variation type IB / EMA/VR/0000176853                   | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted To update sections 4.4 and 4.8 of the of the SmPC information concerning bone effects and the adverse reaction bone mineral density decreased with a frequency of common. Sections 2 and 4 of the PL have | 13/06/2024 | 27/09/2024 | SmPC and PL            |

<div style=\"page-break-after: always\"></div>

|                                       | been updated accordingly. In addition, the MAH has updated the details for the local representatives in AT, BE, CY, ET, EL, ES, HU, IE, IT, LT, LU, LV & PL and made some minor linguistic corrections. In addition, the MAH has updated the list of local representatives for AT, BE, ET, EL, IE, IT, CY, LV, LT, LU, HU and PL.   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000177640 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Minor change of an analytical procedure for an in-process control - Accepted                                                                                                                                      | 08/05/2024 | N/A |